Atlas Trials

Shanghai Miracogen Inc.

21 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Shanghai Miracogen Inc.

RecordFirmDate
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT06976190)Shanghai Miracogen Inc.2025-05-06
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer (NCT05754853)Shanghai Miracogen Inc.2023-04-06
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma (NCT05126719)Shanghai Miracogen Inc.2023-04-06
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN (NCT05751512)Shanghai Miracogen Inc.2023-03-01
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. (NCT05338957)Shanghai Miracogen Inc.2022-08-05
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors (NCT05688605)Shanghai Miracogen Inc.2022-06-30
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients (NCT05263869)Shanghai Miracogen Inc.2022-03-23
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. (NCT05141747)Shanghai Miracogen Inc.2022-01-19
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). (NCT05141786)Shanghai Miracogen Inc.2021-12-01
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04924699)Shanghai Miracogen Inc.2021-06-30
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer (NCT04837508)Shanghai Miracogen Inc.2021-06-07
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer (NCT04492488)Shanghai Miracogen Inc.2021-05-24
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. (NCT05188209)Shanghai Miracogen Inc.2021-05-24
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) (NCT04742153)Shanghai Miracogen Inc.2021-05-13
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer (NCT04838964)Shanghai Miracogen Inc.2021-04-28
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (NCT04868162)Shanghai Miracogen Inc.2021-04-23
A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer (NCT04839510)Shanghai Miracogen Inc.2021-04-20
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer (NCT04838548)Shanghai Miracogen Inc.2020-09-04
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors (NCT04941339)Shanghai Miracogen Inc.2018-11-21
A Study of MRG003 in Patients With Advanced Solid Tumors (NCT04868344)Shanghai Miracogen Inc.2018-05-09

Track Shanghai Miracogen Inc. automatically

Every clearance here is in the API, with alerts when new ones post.